ARK's $10M Flow: Assessing How Liquidity Affects CRISPR and PayPay

ARK Invest's Recent Strategic Moves

On March 12, ARK Invest made a focused investment of $4.7 million in CRISPR Therapeutics, increasing its stake in the company by 1.25%. This was the largest single CRISPR trade for the ETF this month, continuing a recent trend of active buying. While significant, this trade is part of a much broader pattern of capital deployment by ARK.

Earlier in the month, ARK made an even larger move, allocating approximately $16.15 million across Coinbase and Robinhood. This single trading day represented a substantial portion of ARK's typical monthly activity. In comparison, the CRISPR investment, though notable, was a smaller piece of the overall capital flow.

These actions highlight ARK's dynamic approach, taking advantage of market pullbacks to build positions. The nearly $5 million invested in PayPay during its IPO last week further illustrates this consistent strategy, as ARK continues to target both new market entrants and established companies.

Market Response: Liquidity and Positioning

ARK's trades have had immediate effects on share prices. The ETF's close to $5 million purchase of PayPay shares coincided with the company's IPO, helping drive a 13.50% surge in the stock on its first day. This demonstrates how concentrated buying by a prominent fund manager can provide a strong initial boost.

For CRISPR, the impact was more moderate but still measurable. The $4.7 million investment on March 12 increased ARK's holding by 1.25%. Given CRISPR's $4.69 billion market cap, this represented a 0.1% increase in the company's available shares. While not a dramatic shift, it adds to ARK's ongoing accumulation, with over $20 million in CRISPR shares purchased since late January.

These moves are part of a broader portfolio realignment. ARK has been reducing exposure to large-cap names like Tesla and Shopify while increasing investments in biotech firms such as CRISPR. This signals a shift from mega-cap technology stocks toward more focused, high-growth opportunities in the biotech sector, often using market downturns as entry points.

Looking Ahead: Key Drivers and Milestones

PayPay's IPO served as the immediate catalyst for ARK's recent investment. The fund's nearly $5 million stake was acquired as the company offered 54.99 million American depositary shares at $16 each, giving ARK about a 2.5% ownership in the new listing. The main factor to watch now is whether trading volume and price momentum can be sustained following the IPO, especially after the initial surge.

For CRISPR, future flows will be influenced by clinical and regulatory developments. The company reported $54 million in Q4 revenue from Casgevy, its first approved therapy, signaling strong commercial progress. ARK's growing position, now valued at over $551 million, reflects optimism about CRISPR's prospects. Upcoming regulatory submissions for Casgevy in younger patients and other clinical updates expected in 2026 will be crucial milestones that could impact the stock's performance and help it reach analyst targets.

In summary, ARK's recent trades are deliberate bets on specific, near-term events. The focus for PayPay is on post-IPO trading dynamics, while for CRISPR, the emphasis is on regulatory and clinical advancements. Tracking these developments will help determine whether ARK's investments are capturing real momentum or simply following market trends.